Detalhe da pesquisa
1.
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2040-2051, 2018 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280635
2.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lancet
; 393(10183): 1819-1830, 2019 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30955977
3.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 375(19): 1823-1833, 2016 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27718847
4.
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med
; 372(21): 2018-28, 2015 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25891174
5.
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Lancet Oncol
; 18(12): 1600-1609, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29129441
6.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Lancet
; 387(10027): 1540-1550, 2016 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26712084
7.
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
Lancet Oncol
; 16(4): 447-56, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25800891
8.
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Br J Haematol
; 167(2): 185-93, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25040094
9.
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Expert Rev Anticancer Ther
; 22(4): 383-400, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35260027
10.
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1âPositive, Advanced NonâSmall-Cell Lung Cancer in the KEYNOTE-010 Study.
J Clin Oncol
; 38(14): 1580-1590, 2020 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32078391
11.
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
J Thorac Oncol
; 14(5): 793-801, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30711649
12.
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
Lancet Respir Med
; 7(4): 347-357, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30876831
13.
Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 19(5): e783-e799, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29983370
14.
Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
Clin Lung Cancer
; 19(5): e629-e645, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29885945
15.
Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.
Arch Pathol Lab Med
; 140(11): 1243-1249, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27552095
16.
Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis.
Cancer
; 101(12): 2755-9, 2004 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15536625